Compared with well-established docetaxel-resistant prostate cancer subclones such as PC-3-DR and DU145-DR used in the previous studies [46–48], 22Rv1 has been shown to express full-length AR and its aggressive variant AR-V7 [49, 50], which reflects a real-world condition in patients with advanced prostate cancer in recent years. This evidence concerns the gene AR and prostate carcinoma.